Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Investor Presentation (February 2020)
45 slides from Jubilant Pharmova's investor presentation, February 2020
Slide 1: Jubilant Life Sciences Limited Investor Presentation
Jubilant Life Sciences Limited Investor Presentation February 2020
Slide 2: Disclaimer
Disclaimer Important Disclaimer This presentation (the “Presentation”, or the “document”) has been prepared by Jubilant Life Sciences Limited (the “Company”) for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for
Slide 3: Jubilant Life Sciences Overview
Jubilant Life Sciences Overview Pharmaceuticals Life Science Ingredients DDDS1 Specialty Pharmaceuticals Drug Discovery Radiopharma Specialty Intermediates Services (Jubilant Allergy Therapy Products Biosys & Jubilant Chemsys) CDMO CMO of Sterile Injectables and Non Sterile Products Nutritiona
Slide 4: Pharmaceuticals Segment
WV jusiant Pharmaceuticals Segment LIFESCIENCES
Slide 5: Evolution of Jubilant Pharma
Evolution of Jubilant Pharma Revenue Contribution(1) JLL acquired Acquired a majority stake in Acquired Draxis Pharma SGX‐listed high Completed FY19 API business – Cadista Holdings Inc. Inc. in Canada yield bond acquisition of US$761m Nanjangud, (generics pharmaceutical (manufacturer of sterile offe
Slide 6: Radiopharmaceuticals Business
Radiopharmaceuticals Business Market Size of Industry in North America 3.5 Radiopharmaceuticals Industry in North America is US$2.4bn, expected to grow at CAGR of 6.2% to reach 2.9 3.0 3.2 2.6 2.7 2.2 2.3 2.4 US$3.5bn by 2023 1.9 2.0 Industry (US$bn) Overview (1) Oncology and cardiology diagnosi
Slide 7: Radiopharmacy Business
Radiopharmacy Business # 2 commercial radiopharmacy network(1) in the US, operated under the Jubilant Radiopharmacy brand Facilities include three cyclotrons Multi‐year agreements with GPOs in place Over 50 radiopharmacies spread across 22 states 750+ employees c.3 mn+ doses delivered annually
Slide 8: Allergy Therapy Business
Allergy Therapy Business Allergen Immunotherapy (AIT) Market Size Global AIT market stands at US$1.8bn and is expected to grow at CAGR of 8.9% to reach 2.8 2.6 US$2.8bn by 2022 2.3 0.5 2.1 0.4 1.8 2.0 1.7 0.4 Major growth drivers include the increased prevalence of allergic diseases, reduced tim
Slide 9: Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products
Contract Manufacturing Business – Sterile Injectables and Non‐Sterile Products Global Pharmaceutical CMO Industry Size 125 134 100 109 117 5 5 7 Injectable market stands at US$5.4bn and is expected to outpace the industry (ex API) by growing at a 5 127 12 79 85 92 4 5 11 6 6 73 6 11 4 11 Industry
Slide 10: API Business
API Business Global Market Size : Synthetic API 149 123 131 129 Global Synthetic API market is US$115bn in 2018 and is expected to grow at a 115 Industry 46 62 51 53 (US$bn) CAGR of 6.7% from 2018 to 2022F to reach US$149bn(1) 48 Overview 53% of outsourced API market is generics(1) 67 72 78 83 8
Slide 11: Solid Dosage Formulations Business
Solid Dosage Formulations Business Global Generics Pharmaceuticals Industry Size by Unbranded Generic US Patent Expiry for Small Molecules Sales(1)(3) Global generics pharmaceutical industry stands at US$111bn and is expected to grow at CAGR of 5.2% to reach US$136bn US$ 72.5 bn 136 by 2023 117 12
Slide 12: Life Science Ingredients Segment
Life Science Ingredients Segment
Slide 13: Specialty Intermediates & Nutritional Products
Specialty Intermediates & Nutritional Products Global Market Size ($ Mn) : Speciality Chemicals Global Market Size (KT): Vitamin B3 Global specialty chemicals market is USD 1.1 billion in 2018 and is expected to grow at 5.4% to reach USD 1.2 Industry billion in 2022. Overview Global nutrition ma
Slide 14: Life Science Chemicals
Life Science Chemicals Global Market Size (KT): Acetic Global Market Size (KT): Ethyl Anhydride Acetate Global Acetic Anhydride market is 585 KT in 2018 and is expected to Industry grow at 4.2% to reach 662KT in 2022 Overview Global Ethyl Acetate market is 2046 KT in 2018 and is expected to grow
Slide 15: Jubilant Life Sciences – Key Strengths & Strategies
Jubilant Life Sciences – Key Strengths & Strategies
Slide 16: Jubilant Life Sciences Key Strengths
Jubilant Life Sciences Key Strengths 1 Strong Leadership in Key Products and Markets 2 Global Competitive Edge Due to Low Cost and Vertical Integration 3 De‐risked Business Model With Diverse Sources of Revenue 4 Strong Pipeline of Products with Deep R&D Capabilities 5 High‐Quality, World –Class, Lo
Slide 17: Leading Market Positions in Specialty Pharmaceuticals
Leading Market Positions Across Business Lines, with High Barriers To 1 Entry For Specialty Pharmaceuticals Highlights Entry Barriers #3 radiopharmaceuticals manufacturer in the US (1) Extensive regulatory and licensing requirements #2 commercial radiopharmacy network in the US (1) Specialty P
Slide 18: Global Competitive Edge Due to Low Cost and Vertical Integration
Global Competitive Edge Due to Low Cost and Vertical 2 Integration Vertical integration across the value chain enables cost competitive advantage resulting in higher margins Integrated Operations… Life Sciences Ingredients Radiopharmacies Provides direct access to hospital networks ‐ ability to de
Slide 19: De-risked Business Model With Diverse Sources of Revenue
3 De‐risked Business Model With Diverse Sources of Revenue Presence in niche Specialty businesses that have high barriers to entry Diverse end‐use industry segmentation in Life Science Ingredients with focus on Pharmaceutical and Agrochemical industries Presence across geographic locations ena
Slide 20: Strong Pipeline of Products With Deep R&D Capabilities
4 Strong Pipeline of Products With Deep R&D Capabilities Strong R&D capabilities demonstrated by complex and niche product filings including 505(b)(2) in radiopharma Strong R&D support with a dedicated workforce of more than 500 R&D professionals. Over 852 patents filed till FY19 Strong pipeli
Slide 21: High-Quality, World-Class, Low Cost Manufacturing Footprint
5 High‐Quality, World‐Class, Low Cost Manufacturing Footprint Spokane, Washington, USA Roorkee, Uttarakhand Contract manufacturing of Sterile Generics manufacturing injectable and Allergy therapy Gajraula, Uttar Pradesh Largest integrated facility of Specialty Intermediates and Samlaya, Gujara
Slide 22: Experienced Management Team with High Standards of Corporate Governance
Experienced Management team with high standards of corporate 6 governance Shyam S Bhartia Hari S Bhartia Chairman Co‐Chairman & Managing Director 39 industry years in pharma, specialty 33 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and IT chemicals, foods, oil and ga
Slide 23: Demonstrated Financial Track Record with Strong Revenue Growth
Demonstrated Financial Track Record with Strong Revenue Growth and 7 Attractive Profitability Profile Revenue from Operations1 Total Revenue EBITDA Split1 Reported EBITDA2 Revenue increased at a CAGR of 12% over FY15‐19 and EBITDA 5,826 5,893 5,861 7,518 9,111 6,763 732 1,291 1,370 1,558 1,775 1,4
Slide 24: Growth Strategies and Plans
Growth Strategies and Plans Continue to strengthen leadership positions in key business segments 1 Radiopharma: Achieve market leadership by leveraging leadership in existing products and broad distribution network along with expansion of our product portfolio through launch of niche and different
Slide 25: Growth Strategies and Plans
Growth Strategies and Plans 3 Develop a diverse product and service portfolio through differentiated and complex offerings Specialty Pharmaceuticals Focus: Develop differentiated products in the radiopharmaceuticals and specialty injectables segments catering to the North American market CDMO Fo
Slide 26: Q3 & 9M'FY20 Results Analysis
Q3 & 9M’FY20 Results Analysis
Slide 27: Chairmen's Message
Chairmen’s Message JUBILANT Q3’FY20 PERFORMANCE Revenue at Rs. 2,315 Crore lower by 3% YoY; EBITDA at Rs 513 Crore lower by 2% YoY and higher by 7% QoQ Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co‐Chairman & Managing Director, Jubilant Life Scienc
Slide 28: Update on Reorganization Proposal
Update on Reorganization Proposal Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, the Company has filed with BSE Limited and National Stock Exchange of India Limited the Composite Scheme of Arrangement for amalgamation of certain promoter controlled entities
Slide 29: Q3'FY20 Results Analysis
Q3’FY20 Results Analysis Ww) J' UBILANT ‘LIFESCIENCES
Slide 30: JLL – Q3'FY20 Financial Highlights
JLL – Q3’FY20 Financial Highlights Revenue at Rs 2,315 Crore, a decrease of 3% YoY and an increase of 2% QoQ • Pharmaceuticals revenue at Rs 1,450 Crore, an increase of 2% YoY, contributing 63% to revenue • LSI revenue at Rs 797 Crore decreased by 11% YoY and increased by 6% QoQ • Drug Discovery &
Slide 31: Pharmaceuticals Segment Highlights – Q3'FY20 (1/2)
Pharmaceuticals Segment Highlights – Q3’FY20 (1/2) Particulars1 Q3'FY19 Q3'FY20 % Change Pharmaceuticals revenue at Rs 1,450 Crore, an increase of 2% YoY. Revenue 1,424 1,450 2% Specialty Pharma and CDMO segments increased by 1% YoY and 5% YoY, Specialty Pharma 757 764 1% respectively. Generics
Slide 32: Pharmaceuticals Segment Highlights – Q3'FY20 (2/2)
Pharmaceuticals Segment Highlights – Q3’FY20 (2/2) USFDA Inspection Details Generics1 Facility Last Inspection • Revenue was flat YoY and down 2% QoQ primarily due to lower volumes in some key products due to customer scheduling Montreal, CMO May, 2018 Montreal, Radiopharma Sep, 2017 • Better pricin
Slide 33: LSI Segment Highlights – Q3'FY20
LSI Segment Highlights – Q3’FY20 Particulars1 Q3'FY19 Q3'FY20 % Change LSI revenue at Rs 797 Crore, decreased by 11% YoY and increased by Revenue 899 797 (11%) 6% QoQ. Strong growth witnessed in Specialty Intermediates and Specialty Intermediates 252 293 16% Nutritional Products amid lower revenue
Slide 34: Drug Discovery & Development Solutions – Q3'FY20
Drug Discovery & Development Solutions – Q3’FY20 Particulars1 Q3'FY19 Q3'FY20 % Change Drug Discovery & Development Solutions (DDDS) comprises Revenue 54 68 26% Drug Discovery Services 54 68 26% • Drug Discovery Services business through Jubilant Biosys Proprietary Drug Discovery 0 0 ‐ Limited & J
Slide 35: Proprietary Drug Discovery (Jubilant Therapeutics)
Proprietary Drug Discovery (Jubilant Therapeutics) Jubilant Therapeutics is a patient‐focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases. Our advanced discovery engine integrates structure‐based design and computational architecture to disc
Slide 36: 9M'FY20 Results Analysis
9M’FY20 Results Analysis Ww J' UBILANT ‘LIFESCIENCES
Slide 37: JLL – 9M'FY20 Financial Highlights
JLL – 9M’FY20 Financial Highlights Revenue at Rs 6,763 Crore, increase of 1% from Rs 6,725 Crore in 9M’FY19 • Pharmaceuticals revenue at Rs 4,231 Crore, increased by 7% YoY, contributing 62% to revenue • LSI revenue at Rs 2,356 Crore decreased 11% YoY, contributing 35% to revenue • Drug Discovery
Slide 38: Adjusted Earnings
Adjusted Earnings Rs Crore Consol EBITDA % Change % Change S. No. Particulars Q3'FY19 Q3'FY20 YoY 9M'FY19 9M'FY20 YoY 1 Reported EBITDA 522 513 (2%) 1,423 1,438 1% 2 One‐off Adjustments (5) 3 8 74 3 Adjusted EBITDA 518 516 (0%) 1,432 1,512 6% 4 Reported EBITDA Margin 22.0% 22.2% 21.2% 21.3% 5 Adjust
Slide 39: Pharmaceuticals Segment Highlights – 9M'FY20
Pharmaceuticals Segment Highlights – 9M’FY20 Particulars1 9M'FY19 9M'FY20 % Change Geography Wise Revenue1 Revenue 3,943 4,231 7% 3,211 3,495 Specialty Pharma 2,134 2,233 5% CDMO 1,024 1,148 12% 98 106 378 341 256 289 Generics 786 850 8% Reported EBITDA 1,087 1,127 4% India North Europe & ROW Adjust
Slide 40: LSI Segment Highlights – 9M'FY20
LSI Segment Highlights – 9M’FY20 Particulars1 9M'FY19 9M'FY20 % Change LSI revenue at Rs 2,356 Crore, decrease of 11% YoY Revenue 2,633 2,356 (11%) Specialty Intermediates Specialty Intermediates 683 831 22% • Revenue increase of 22% YoY led by strong demand and better prices in Nutritional Produc
Slide 41: Drug Discovery & Development Solutions – 9M'FY20
Drug Discovery & Development Solutions – 9M’FY20 Particulars1 9M'FY19 9M'FY20 % Change DDDS segment revenue increased 18% YoY to Rs 176 Crore led Revenue 149 176 18% by growth in Drug Discovery Services business, which was Drug Discovery Services 149 176 18% Proprietary Drug Discovery 0 0 ‐ driven
Slide 42: Debt Profile
Debt Profile Particulars 31/03/19 30/09/19 30/12/19 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Subsidiaries 500 500 400 Total 500 500 400 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,341 1,029 1,156 Subsidiaries 61 21 37 Total 1,402 1,050 1,193 Gross Debt (Rs. Crs) (Rs. Crs) (Rs. Crs) Sta
Slide 43: Appendix
Appendix 4 J' UBILANT LIFESCIENCES
Slide 44: Income Statement – Q3 & 9M'FY20
Income Statement – Q3 & 9M’FY20 Particulars1 Q3'FY19 Q3'FY20 YoY Growth 9M'FY19 9M'FY20 YoY Growth FY'19 Total Revenue from Operations 2,377 2,315 (3%) 6725 6,763 1% 9,111 Pharmaceuticals 1,424 1,450 2% 3943 4,231 7% 5,349 Life Science Ingredients 899 797 (11%) 2633 2,356 (11%) 3,545 Drug Discovery
Slide 45: Corporate Actions
Corporate Actions For Investors: Ravi Agrawal / Vineet Mayer Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 / 1021 Ph: +91 22 6645 1209 E‐mail: ravi.agrawal@jubl.com E‐mail: siddharth@cdr‐india.com Vineet.mayer@jubl.com For Media: Sudhakar Safaya Gaurav Kashyap Jub
Jubilant Life Sciences — Investor Presentation (February 2020) on 6ix